Abstract | STATEMENT OF PROBLEM: METHOD OF STUDY: Out of 46 patients with diagnosis of epistaxis due to HHT who started treatment with tamoxifen 20 mg/d, 38 patients completed a mean of 23.4 months of treatment. All patients filled out a self-assessment questionnaire of rhinologic Quality of Life and epistaxis grading scale. MAIN RESULTS: The bleeding score and the Quality of Life score improved. Hemoglobin concentration also improved. None of the patients needed blood transfusions during the treatment period. Only one patient had minor side effects of the drug. PRINCIPAL CONCLUSIONS:
|
Authors | E Yaniv, M Preis, J Shevro, B Nageris, T Hadar |
Journal | Rhinology
(Rhinology)
Vol. 49
Issue 2
Pg. 214-6
(Jun 2011)
ISSN: 0300-0729 [Print] Netherlands |
PMID | 21743879
(Publication Type: Journal Article, Randomized Controlled Trial)
|
Chemical References |
- Estrogen Antagonists
- Tamoxifen
|
Topics |
- Adult
- Epistaxis
(drug therapy, etiology)
- Estrogen Antagonists
(therapeutic use)
- Female
- Humans
- Male
- Middle Aged
- Quality of Life
- Tamoxifen
(therapeutic use)
- Telangiectasia, Hereditary Hemorrhagic
(complications, drug therapy)
|